BACKGROUND: The incidence and severity of Clostridium difficile infections are increasing, and there is a need to optimize the prevention of complicated disease. OBJECTIVE: To identify modifiable processes of care associated with an altered risk of C difficile complications. METHODS: A retrospective cohort study (with prospective case ascertainment) of all C difficile infections during 2007⁄2008 at a tertiary care hospital was conducted. RESULTS: Severe complications were frequent (occurring in 97 of 365 [27%] C difficile episodes), with rapid onset (median three days postdiagnosis). On multivariable analysis, nonmodifiable predictors of complications included repeat infection (OR 2.67), confusion (OR 2.01), hypotension (OR 0.97 per increased mmHg) and elevated white blood cell count (OR 1.04 per 109 cells⁄L). Protection from complications was associated with initial use of vancomycin (OR 0.24); harm was associated with ongoing use of exacerbating antibiotics (OR 3.02). CONCLUSION: C difficile infections often occur early in the disease course and are associated with high complication rates. Clinical factors that predicted a higher risk of complications included confusion, hypotension and leukocytosis. The most effective ways to improve outcomes for patients with C difficile colitis are consideration of vancomycin as first-line treatment for moderate to severe cases, and the avoidance of unnecessary antibiotics.
BACKGROUND: The incidence and severity of Clostridium difficile infections are increasing, and there is a need to optimize the prevention of complicated disease. OBJECTIVE: To identify modifiable processes of care associated with an altered risk of C difficile complications. METHODS: A retrospective cohort study (with prospective case ascertainment) of all C difficile infections during 2007⁄2008 at a tertiary care hospital was conducted. RESULTS: Severe complications were frequent (occurring in 97 of 365 [27%] C difficile episodes), with rapid onset (median three days postdiagnosis). On multivariable analysis, nonmodifiable predictors of complications included repeat infection (OR 2.67), confusion (OR 2.01), hypotension (OR 0.97 per increased mmHg) and elevated white blood cell count (OR 1.04 per 109 cells⁄L). Protection from complications was associated with initial use of vancomycin (OR 0.24); harm was associated with ongoing use of exacerbating antibiotics (OR 3.02). CONCLUSION: C difficile infections often occur early in the disease course and are associated with high complication rates. Clinical factors that predicted a higher risk of complications included confusion, hypotension and leukocytosis. The most effective ways to improve outcomes for patients with C difficile colitis are consideration of vancomycin as first-line treatment for moderate to severe cases, and the avoidance of unnecessary antibiotics.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Dick E Zoutman; B Douglas Ford; Elizabeth Bryce; Marie Gourdeau; Ginette Hébert; Elizabeth Henderson; Shirley Paton Journal: Am J Infect Control Date: 2003-08 Impact factor: 2.918
Authors: C Thongprayoon; W Cheungpasitporn; P Phatharacharukul; P J Edmonds; Q Kaewpoowat; P Mahaparn; J Bruminhent; S B Erickson Journal: Int J Clin Pract Date: 2015-07-05 Impact factor: 2.503
Authors: Travis J Carlson; Anne J Gonzales-Luna; Kimberly Nebo; Hannah Y Chan; Ngoc-Linh T Tran; Sheena Antony; Chris Lancaster; M Jahangir Alam; Khurshida Begum; Kevin W Garey Journal: Open Forum Infect Dis Date: 2020-10-07 Impact factor: 3.835
Authors: Raina Shivashankar; Sahil Khanna; Patricia P Kammer; W Scott Harmsen; Alan R Zinsmeister; Larry M Baddour; Darrell S Pardi Journal: Clin Gastroenterol Hepatol Date: 2013-05-20 Impact factor: 11.382
Authors: Domonkos Trásy; Krisztián Tánczos; Márton Németh; Péter Hankovszky; András Lovas; András Mikor; Edit Hajdú; Angelika Osztroluczki; János Fazakas; Zsolt Molnár Journal: J Immunol Res Date: 2016-08-15 Impact factor: 4.818